Search

Displaying results 4091 - 4100 of 10000 in total
  1. Drug

    19-norandrostenedione

    go.drugbank.com/drugs/DB01434
    ExperimentalIllicit

    After 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.

  2. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  3. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

  4. Drug

    Elafin

    go.drugbank.com/drugs/DB05161
    Investigational

    The excellent tolerability of Elafin in human subjects was demonstrated in a Phase I clinical single dose escalating study. … Elafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system.

  5. Drug

    Cefamandole

    go.drugbank.com/drugs/DB01326
    ApprovedWithdrawn

    It is no longer marketed in the United States.

    Synonyms: (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid, (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  6. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  7. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent.

  8. Drug

    beta-Hydroxyisovaleric acid

    go.drugbank.com/drugs/DB15344
    Investigational

    beta-Hydroxyisovaleric acid is under investigation in clinical trial NCT03018496 (Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.).

  9. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  10. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.